Liquidia Co. (NASDAQ:LQDA) Given Average Rating of “Moderate Buy” by Brokerages

Liquidia Co. (NASDAQ:LQDA) has received an average rating of “Moderate Buy” from the six ratings firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $21.00.

A number of research firms recently weighed in on LQDA. Oppenheimer initiated coverage on Liquidia in a report on Tuesday, June 25th. They issued a “market perform” rating for the company. HC Wainwright restated a “buy” rating and set a $32.00 price objective on shares of Liquidia in a research report on Wednesday, May 15th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $28.00 price target on shares of Liquidia in a research report on Monday, June 3rd.

Insider Activity

In other news, General Counsel Russell Schundler sold 2,060 shares of the company’s stock in a transaction on Friday, April 12th. The shares were sold at an average price of $14.58, for a total value of $30,034.80. Following the completion of the transaction, the general counsel now owns 486,027 shares in the company, valued at approximately $7,086,273.66. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, CEO Roger Jeffs sold 8,360 shares of the firm’s stock in a transaction dated Friday, April 12th. The shares were sold at an average price of $14.58, for a total value of $121,888.80. Following the completion of the sale, the chief executive officer now owns 826,985 shares in the company, valued at $12,057,441.30. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, General Counsel Russell Schundler sold 2,060 shares of Liquidia stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $14.58, for a total value of $30,034.80. Following the completion of the sale, the general counsel now owns 486,027 shares in the company, valued at $7,086,273.66. The disclosure for this sale can be found here. In the last three months, insiders have sold 18,653 shares of company stock worth $270,409. 31.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Liquidia

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Fortitude Family Office LLC purchased a new position in shares of Liquidia during the 4th quarter worth approximately $26,000. Aigen Investment Management LP acquired a new stake in shares of Liquidia during the third quarter valued at $80,000. Tower Research Capital LLC TRC increased its position in Liquidia by 610.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,997 shares of the company’s stock worth $108,000 after purchasing an additional 7,731 shares in the last quarter. Corton Capital Inc. raised its stake in Liquidia by 14.2% in the 3rd quarter. Corton Capital Inc. now owns 23,440 shares of the company’s stock valued at $149,000 after purchasing an additional 2,921 shares during the last quarter. Finally, Greenleaf Trust purchased a new position in Liquidia in the 4th quarter valued at about $164,000. 64.54% of the stock is owned by institutional investors and hedge funds.

Liquidia Price Performance

Shares of LQDA stock opened at $12.00 on Tuesday. The business has a fifty day moving average of $12.84 and a 200 day moving average of $13.24. The firm has a market capitalization of $916.20 million, a price-to-earnings ratio of -7.69 and a beta of 0.25. Liquidia has a 1 year low of $5.71 and a 1 year high of $16.99.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Monday, May 13th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.22). The business had revenue of $2.97 million for the quarter, compared to analyst estimates of $4.31 million. Liquidia had a negative net margin of 674.42% and a negative return on equity of 177.83%. As a group, equities research analysts expect that Liquidia will post -1.32 earnings per share for the current year.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).